Table 2

Preoperative baseline measurements and postoperative changes in the separate procedural groups

TAVISAVRANOVA
Baseline6 monthsBaseline6 monthsp Value
Left ventricle
 LVEDVI (ml/m2)94±1890±2092±1974±12**0.04
 LVESVI (ml/m2)46±1841±17*44±2232±6*0.19
 LVSVI (ml/m2)48±1050±1049±842±7*0.14
 LVEF (%)52±1256±10*55±1157±80.57
 LVM (g)153±48120±38***143±57114±42***0.53
 LVMI (g/m2)83±2065±17**74±1159±8**0.35
 LVM/LVEDV (g/ml)0.88±0.20.73±0.2***0.80±0.10.81±0.20.001
Right ventricle
 RVEDVI (ml/m2)77±1974±1378±1476±170.60
 RVESVI (ml/m2)38±1335±10*31±734±100.80
 RVSVI (ml/m2)39±939±947±1141±140.37
 RVEF (%)51±953±1060±854±11*0.63
 RVMI (g/m2)19±416±3**18±417±40.17
Aortic valve
 Mean PG (mm Hg)58 (43–73)21±8***51 (37–66)35±13**0.017
 AR fraction (%)16±118±6*18±710±110.46
Mitral valve
 MR fraction (%)20±1614±232±82±60.007
Late gadolinium enhancement
Focal myocardial fibrosis
 Mass (g)14.1±88.6±5***5.9±35.1±30.005
 Percentage myocardium (%)10.9±68.5±5*4.2±24.1±20.02
Myocardial scar (infarction)
 Mass (g)20.6±1213.8±11*22.718.00.80
 Percentage myocardium (%)15.6±1011.2±910.010.00.12
  • Values are mean±SD or median (interquartile range).

  • ANOVA repeated measure overtime with procedure as covariate. Paired t test vs baseline: *p<0.05, **p<0.01, ***p<0.001.

  • AR, aortic regurgitation; EDVI, end diastolic volume indexed to body surface area; EF, ejection fraction; ESVI, end systolic volume indexed; LV, left ventricle; LVM, left ventricular mass; mean PG, peak pressure gradient; MR, mitral regurgitation; RV, right ventricle; SVI, stroke volume indexed; TAVI, transcatheter aortic valve implantation.